VANCOUVER, BC, July 6, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended May 31, 2022, after market close on Thursday, July 14, 2022. Interested parties are invited to…


Previous articleAlgernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate
Next articleAlgernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study